Trulicity Dosing: FDA-Label Range, Titration, and Format

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide is part of the PlexusDx Education Hub — plain-language explainers on GLP-1 biology, weight-management protocols, and the genetic factors that sit underneath every metabolic decision.

People searching "Trulicity dosing" usually want the same clear facts: what doses the label defines, how the medication is delivered, and why the numbers step up over time. Those answers live in the FDA label for dulaglutide, and this guide reports them plainly. What it will not do is recommend a schedule — that is a decision for a provider who knows your full medical history.

The FDA-label dose range

Per the Trulicity FDA label, dosing begins at a 0.75 mg starting dose, with maintenance doses of 1.5 mg, 3 mg, or 4.5 mg per week. Trulicity is administered as a once-weekly subcutaneous injection delivered through a single-dose pen. The label describes a graduated titration concept: start at the lowest dose so the body can adapt to GLP-1 pathway activation, then increase under prescriber supervision according to tolerability and response.

Why the dose steps up gradually

Slow titration is standard across the GLP-1 class because gastrointestinal side effects, nausea in particular, are most pronounced during dose escalation. The label's titration schedule is designed to reduce intolerable symptoms while maintaining therapeutic momentum. Real-world data associate skipping or accelerating titration with higher discontinuation rates, which is why the measured step-up path is the norm.

What a provider weighs on dose

Dose selection, titration speed, and later adjustments for Trulicity are individualized clinical decisions. Typical discussion points include baseline metabolic status, kidney function, gastrointestinal history, prior medication tolerability, and the FDA-approved indication the prescription is written for. Across all of it, one rule holds: never adjust GLP-1 receptor agonist dosing on your own.

The single-dose pen format

Trulicity's once-weekly single-dose pen is central to how the medication is used, but the full administration protocol — timing, storage, and any technique guidance — lives in the FDA label and the patient information leaflet that ships with the medication. Your prescriber and pharmacist walk you through it. This article stops at reporting the dose range and format rather than offering how-to steps.

The genetic context underneath dosing

Upstream of any GLP-1 protocol decision, the PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape baseline GLP-1, appetite regulation, and energy balance. That context is the test before you invest framing PlexusDx applies to every protocol conversation. Note that PlexusDx does not sell, prescribe, or recommend dulaglutide; its own protocols cover semaglutide and tirzepatide.

To explore that route, the PlexusDx Weight Management Protocols publish per-protocol details on their product pages. The genetic test never predicts response to Trulicity or any medication — it simply maps the pathway biology that shapes the broader picture.

Why reporting differs from prescribing

This guide reports the dose range and format that the label defines, but it deliberately avoids telling anyone which schedule to follow. The distinction matters: knowing that a starting dose and several maintenance doses exist is helpful context, while deciding which applies to you — and how quickly to move between steps — is a clinical judgment that depends on your history, kidney function, tolerability, and the indication on your prescription. If a titration week proves difficult, that too is a provider conversation, not a self-directed adjustment. Understanding the structure of the schedule simply lets you ask sharper questions when you sit down with your clinician.

The value of understanding Trulicity dosing is not that it lets you self-manage — it does not — but that it lets you participate. Knowing the label range and why titration is graduated helps you follow your provider's plan closely and recognize when a difficult week is worth flagging.

Frequently Asked Questions

What is the FDA-approved dosing for Trulicity?

Per the Trulicity FDA label, dosing begins at 0.75 mg, with maintenance doses of 1.5 mg, 3 mg, or 4.5 mg per week, following a graduated titration approach. Specific dose selection and titration speed are individualized clinical decisions. Always follow the schedule your prescriber sets, and never adjust GLP-1 dosing on your own.

How is Trulicity administered?

Trulicity is given as a once-weekly subcutaneous injection through a single-dose pen. The complete administration protocol — timing, storage, and any injection-technique guidance — appears in the FDA label and the patient information leaflet included with the medication. Your prescriber and pharmacist will walk you through the specifics.

Why does Trulicity use a titration schedule?

Titration reduces gastrointestinal side effects such as nausea, vomiting, and diarrhea that are most pronounced during dose escalation. The graduated schedule lets the body adapt to GLP-1 pathway activation and improves tolerability. Real-world data link skipped titration to higher discontinuation rates, which is why the step-up approach is standard.

Can genetics guide my Trulicity dose?

No. The Precision Peptide Genetic Test does not predict Trulicity dose response or titration tolerability. It reads pathway-level variants in genes such as FTO and GLP1R that shape baseline GLP-1 biology, offering context for a broader protocol conversation with a healthcare provider rather than functioning as a dose-selection tool.

Keep reading across the PlexusDx Education Hub for more evidence-based GLP-1 and peptide explainers.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.